

This listing of claims will replace all prior versions, and listings, of claims in our amendments or responses to Office actions.

**Listing of Claims:**

Claims 1-30 (canceled)

Claim 31 (currently amended). An isolated or purified antibody or binding fragment of an antibody, which specifically binds to a cytokine complex comprising a mature polypeptide of SEQ ID NO: 2 or 4 and a mature polypeptide of SEQ ID NO: 12 or 13, wherein the antibody or binding fragment thereof does not bind to SEQ ID NO: 2, 4, 12, or 13 individually.

Claim 32 (canceled).

Claim 33 (previously added). The antibody or binding fragment of claim 31, wherein the cytokine complex comprises a mature polypeptide of SEQ ID NO: 2 and a mature polypeptide of SEQ ID NO: 12.

Claim 34 (previously added). The antibody or binding fragment of claim 33 which is an agonist antibody or binding fragment.

Claim 35 (previously added). The antibody or binding fragment of claim 34, wherein the agonist antibody or binding fragment enhances the binding of the cytokine complex to a receptor complex comprising CNTFR, LIFR, and gp130.

Claim 36 (previously added). The antibody or binding fragment of claim 35, wherein the receptor complex comprises human CNTFR, human LIFR, and human gp130.

Claim 37 (previously added). The antibody or binding fragment of claim 31, which is an antagonist antibody or binding fragment.

Claim 38 (previously added). The antibody or binding fragment of claim 37, wherein the antagonist antibody inhibits binding of the cytokine complex to a receptor complex comprising CNTFR, LIFR, and gp130.

Claim 39 (previously added). The antibody or binding fragment of claim 38, wherein the receptor complex comprises human CNTFR, human LIFR, and human gp130.

Claim 40 (previously added). The antibody or binding fragment of claim 31, wherein the binding fragment is selected from the group consisting of: a Fab fragment, a Fab2 fragment, a single chain antibody, and an Fv fragment.

Claim 41 (previously added). The antibody or binding fragment of claim 31, wherein the antibody is a polyclonal antibody.

Claim 42 (previously added). The antibody or binding fragment of claim 31, wherein the antibody is a monoclonal antibody.

Claim 43 (previously added). The antibody or binding fragment of claim 31, wherein the antibody is a recombinant antibody.

Claim 44 (previously added). The antibody or binding fragment of claim 31, wherein the antibody is selected from the group consisting of: a humanized antibody, a chimeric antibody, a fully human antibody.

Claim 45 (previously added). The antibody or binding fragment of claim 31, which is detectably labeled.

Claim 46 (previously added). A composition comprising the antibody or binding fragment of claim 31 and an aqueous carrier.

Claim 47 (previously added). The composition of claim 46, wherein the aqueous carrier is selected from the group consisting of: water, saline, and a buffer.

Claim 48 (previously added). The composition of claim 46, wherein the aqueous carrier is a pharmaceutically acceptable aqueous carrier.

Claim 49 (previously added). A kit comprising the antibody or binding fragment of claim 31, a compartment containing the antibody or binding fragment, and instructions for use or disposal of reagents in the kit.

Claim 50 (new). The antibody or binding fragment of claim 31, wherein the antibody or binding fragment binds with a  $K_D$  of at least 30  $\mu\text{M}$ .

Claim 51 (new). The antibody or binding fragment of claim 31, wherein the antibody or binding fragment binds with a  $K_D$  of at least 10  $\mu\text{M}$ .

Claim 52 (new). The antibody or binding fragment of claim 31, wherein the antibody or binding fragment binds with a  $K_D$  of at least 3  $\mu\text{M}$ .